Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements
Condition(s):Intrahepatic Cholangiocarcinoma; FGFR2 Gene Mutation; FGFR2 Gene Rearrangement; FGFR2 Gene TranslocationLast Updated:August 28, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Intrahepatic Cholangiocarcinoma; FGFR2 Gene Mutation; FGFR2 Gene Rearrangement; FGFR2 Gene TranslocationLast Updated:August 28, 2023Recruiting
Condition(s):Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic CancerLast Updated:June 4, 2013Completed
Condition(s):Intrahepatic CholangiocarcinomaLast Updated:April 4, 2022Withdrawn
Condition(s):CholangiocarcinomaLast Updated:July 29, 2020Unknown status
Condition(s):Biliary Tract Carcinoma; Cholangiocarcinoma; Bile Duct CancerLast Updated:March 26, 2024Recruiting
Condition(s):Hepatobiliary Cancer; Liver Cancer; Cholangiocarcinoma; Hepatocellular CarcinomaLast Updated:January 16, 2024Recruiting
Condition(s):Intrahepatic CholangiocarcinomaLast Updated:September 13, 2023Recruiting
Condition(s):Extrahepatic Cholangiocarcinoma; Bile Duct CancerLast Updated:February 21, 2023Recruiting
Condition(s):Carcinoma; Intrahepatic Cholangiocarcinoma; Digestive System Neoplasms; PD-1 Inhibitor; First-line TreatmentLast Updated:June 22, 2023Recruiting
Condition(s):CholangiocarcinomaLast Updated:September 1, 2021Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.